Marché de la marijuana médicale – Analyse des tendances et de la croissance | Année de prévision 2031

  • Report Code : TIPRE00022901
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 181
Buy Now

Le marché de la marijuana médicale était évalué à 11 706,50 millions de dollars américains en 2021 et devrait atteindre sa valeur de 40 027,59 millions de dollars d'ici 2028 ; on estime qu'il croîtra à un TCAC de 19,2 % de 2022 à 2028.



La marijuana médicale, également connue sous le nom de cannabis médical, gagne en popularité de jour en jour en raison de son application croissante dans le domaine thérapeutique. Il est dérivé de la plante Cannabis sativa, qui peut être utilisée pour le traitement des maladies chroniques et la gestion de la douleur.



Le marché de la marijuana médicale est segmenté en produit, application, canal de distribution et zone géographique. Par géographie, le marché est largement segmenté en Amérique du Nord, Europe, Asie-Pacifique, Moyen-Orient & Afrique et Sud & Amérique centrale. Ce rapport offre des informations et une analyse approfondie du marché en mettant l'accent sur des paramètres tels que les tendances et la dynamique du marché et l'analyse concurrentielle des principaux acteurs du marché mondial.  



< span>Insights stratégiques



Régions lucratives pour le marché de la marijuana médicale



Régions lucratives pour le marché de la marijuana médicale



< h3>Informations sur le marché

Augmentation des approbations de produits à base de cannabis médical



Le potentiel médicinal de la marijuana a incité divers chercheurs et entreprises à utiliser la marijuana dans des applications médicales. Par exemple, le tétrahydrocannabinol (THC) est principalement utilisé pour la fabrication de médicaments. La Food and Drug Administration (FDA) des États-Unis a approuvé des médicaments à base de THC tels que Cesamet, qui contient de la naboline comme ingrédient actif, qui est un produit dérivé synthétiquement qui a une structure similaire au THC. Cesamet est prescrit pour le traitement des nausées chez les patients recevant une chimiothérapie. Cesamet est généralement prescrit lorsque d'autres médicaments ne peuvent pas contrôler les nausées et les vomissements. La FDA a également approuvé le Marinol et le Syndros à des fins thérapeutiques aux États-Unis. Marinol et Syndros contiennent l'ingrédient actif dronabinol, un 9-THC synthétique considéré comme le composant psychoactif du cannabis. Les médicaments Marinol et Syndros sont prescrits pour stimuler l'appétit chez les patients atteints du syndrome de dépérissement développé comme l'une des indications du SIDA. De même, divers produits à base de marijuana ont été approuvés ou sont en cours d'essais cliniques. Par exemple, le nabiximols (Sativex) est un médicament approuvé commercialisé au Canada. Le nabiximols est un extrait de cannabis utilisé pour traiter la spasticité et les douleurs neuropathiques liées à la la sclérose en plaques< /a>. Il est formulé avec une combinaison de THC et d'autres cannabidiols (CBD). En février 2020, CanaQuest Medical Corp, une entreprise canadienne, a demandé l'approbation de la production et de la commercialisation du Mentabinol à Santé Canada. Le mentabinol est un produit à base de THC et sa demande d'approbation a été déposée en vertu de la Loi sur le cannabis. L'augmentation de l'approbation des produits à base de marijuana mentionnés ci-dessus par la FDA stimule la croissance du marché de la marijuana médicale. 



Insights basés sur les produits



Sur la base du produit, le marché de la marijuana médicale est divisé en forme séchée et en forme d'extrait. Le segment de la forme d'extrait détenait une plus grande part de marché en 2021. De plus, le même segment devrait enregistrer un TCAC plus élevé de 19,3 % au cours de la période de prévision. La croissance du segment des extraits peut être attribuée à la demande croissante d'extraits liquides dans les applications médicales, à l'augmentation des tendances en matière de santé et de bien-être avec la consommation de produits de santé naturels et à la sensibilisation croissante aux avantages des extraits par rapport à la marijuana séchée.



Marché de la marijuana médicale, par Produit - 2021 et 2028



Marché de la marijuana médicale, par produit - 2021 et 2028< /p>

Insights basés sur les applications



Sur la base des applications, le marché de la marijuana médicale est segmenté en gestion de la douleur, syndrome de Tourette, maladie d'Alzheimer, migraines, dépression et anxiété, sclérose en plaques, cancer et autres. Le segment anti-douleur détenait la plus grande part de marché dans 2021. Cependant, le segment de la sclérose en plaques devrait enregistrer le TCAC le plus rapide de 20,3 % de 2022 à 2028. Le segment de la gestion de la douleur est entraîné par la prévalence croissante des traumatismes ou de l'hypertension, la demande croissante de stimulateurs musculaires et nerveux et la prévalence croissante des troubles du mode de vie tels que l'obésité et le diabète.



Canal de distribution -Insights basés sur



Selon le canal de distribution, le médecin Le marché de la marijuana est segmenté en pharmacie de détail, commerce électronique et autres. Le segment de la pharmacie de détail détenait la plus grande part de marché en 2021. Cependant, le segment du commerce électronique devrait enregistrer le TCAC le plus rapide de 19,8 % au cours de la période 2022-2028. Les principaux facteurs déterminants pour le segment de la pharmacie de détail sont une chaîne d'approvisionnement hautement réglementée, des conseils d'experts et des solutions pour les patients qui améliorent l'observance.



Les développements organiques tels que les lancements et les approbations de produits sont des stratégies largement adoptées par les entreprises opérant sur le marché de la marijuana médicale. Quelques-uns des développements clés récents du marché sont répertoriés ci-dessous :



En février 2021, CANAQUEST MEDICAL CORP a annoncé une nouvelle entente de production et de distribution avec PurCann Pharma («PurCann») et SiliCycle Inc. («SiliCycle»). Cet accord facilite la production, la distribution et l'exportation mondiale prévues par CanaQuest des formulations de mentanine et de mentabinol, par l'intermédiaire de sa filiale en propriété exclusive, ADC BioMedical Corp.



Profils d'entreprise



  • Aphria, Inc.
  • Canopy Growth Corporation
  • CanaQuest Medical Corporation
  • GW Pharmaceuticals
  • Organigram Holdings Inc.
  • VIVO Cannabis Inc
  • Panaxia Pharmaceutical Industries Ltd.
  • Phoena Holdings Inc.
  • Emerald Health Therapeutics Inc.
  • MARICANN INC.
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is the Medical Marijuana market?

Medical marijuana is a term for derivatives of the Cannabis sativa plant that are used to ease symptoms caused by certain medical conditions. Medical marijuana is also known as medical cannabis. Cannabis sativa contains many active compounds. The best known are delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is the primary ingredient in marijuana. Medical marijuana uses the marijuana plant or chemicals in it to treat diseases or conditions. It's basically the same product as recreational marijuana, but it's taken for medical purposes.

Who are the major players in the medical marijuana market?

The medical marijuana market majorly consists of the players such as Aphria, Inc.; Canopy Growth Corporation; CanaQuest Medical Corporation; GW Pharmaceuticals; Organigram Holdings Inc.; VIVO Cannabis Inc.; Panaxia Pharmaceutical Industries Ltd.; Phoena Holdings Inc.; Emerald Health Therapeutics Inc.; and MARICANN INC.

What are the driving factors for the medical marijuana market across the country?

The factors that are driving and restraining factors that will affect the medical marijuana market in the coming years. Factors such as increasing approvals of medical marijuana products and rising acceptance of medicinal use of marijuana in America. However, the illegal use of cannabis as a street drug and misconceptions regarding marijuana is likely to have a negative impact on the growth of the market in the coming years.

Which segment is dominating the medical marijuana market?

The global medical marijuana market based on product is dried form and extract form. The extract form segment is likely to hold the largest share of the market in 2022. Moreover, the segment is anticipated to register the highest CAGR in the market during the forecast period.

The List of Companies - Medical Marijuana Market

  1. Aphria, Inc.
  2. Canopy Growth Corporation
  3. CanaQuest Medical Corporation
  4. GW Pharmaceuticals
  5. Organigram Holdings Inc.
  6. VIVO Cannabis Inc
  7. Panaxia Pharmaceutical Industries Ltd.
  8. Phoena Holdings Inc.
  9. Emerald Health Therapeutics Inc.
  10. MARICANN INC.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports